Chimeric antigen receptor transduced T cells: tuning up for the next generation
Chimeric antigen receptor (CAR) T cell therapy has recently achieved impressive clinical outcome in patients with CD19?positive hematologic malignancies. Extrapolation of CAR T cell treatment to solid tumors, however, has not yet yielded similar results. This might be due to intrinsic causes, e.g. i...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
2018
|
| In: |
International journal of cancer
Year: 2017, Volume: 142, Issue: 9, Pages: 1738-1747 |
| ISSN: | 1097-0215 |
| DOI: | 10.1002/ijc.31147 |
| Online Access: | Verlag, Volltext: http://dx.doi.org/10.1002/ijc.31147 Verlag, Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1002/ijc.31147 
|
| Author Notes: | Maria-Luisa Schubert, Jean-Marc Hoffmann, Peter Dreger, Carsten Müller-Tidow and Michael Schmitt |
| Summary: | Chimeric antigen receptor (CAR) T cell therapy has recently achieved impressive clinical outcome in patients with CD19?positive hematologic malignancies. Extrapolation of CAR T cell treatment to solid tumors, however, has not yet yielded similar results. This might be due to intrinsic causes, e.g. insufficient CAR T cell activation or CAR toxicity as well as extrinsic factors displaying an unfavorable tumor environment for CAR T cells by raising physical and chemical barriers. In this review, we discuss the advantages as well as major obstacles of CAR T cell therapy, particularly in the context of solid tumors, and focus on efforts and novel strategies in CAR T cell development. |
|---|---|
| Item Description: | Published online: 9 Nov 2017 Gesehen am 13.04.2018 |
| Physical Description: | Online Resource |
| ISSN: | 1097-0215 |
| DOI: | 10.1002/ijc.31147 |